What is Restylane Shaype and how does it differ from Sculptra or Radiesse?

Restylane Shaype is a hybrid biostimulator combining PLLA with hyaluronic acid, positioning it between Sculptra (PLLA monotherapy) and Radiesse (CaHA) in the longevity and volumization market. It just received EU approval and is already available in select US markets, offering practices a mid-range option in the biostimulator category.

How much more can I charge for biostimulator fillers compared to regular HA fillers?

Biostimulator fillers like Restylane Shaype command 20–30% premiums over standard hyaluronic acid fillers, making them attractive for practices seeking higher per-syringe revenue without requiring additional treatment sessions.

What does EU CE mark approval mean for US medspa owners?

EU approval is a leading indicator of manufacturer confidence and manufacturing scale, typically preceding expanded US distribution and payer coverage. For Restylane Shaype, the CE mark signals Galderma's commitment to scaling the product, which often translates to broader availability and insurance consideration in US markets.

What should I tell patients about biostimulator filler results and longevity?

Patient education on timeline-to-result and longevity claims is essential to avoid dissatisfaction with biostimulators. Unlike immediate-result HA fillers, biostimulators work over time to stimulate collagen, so setting clear expectations about when results appear and how long they last is critical for retention and referrals.

Is Restylane Shaype available in the US now?

Restylane Shaype has already gained traction in select US markets, though the recent EU approval suggests Galderma is positioning for broader US distribution. Practices should check with their Galderma rep for current availability in their region.

Injectables

Galderma Wins EU Nod for Restylane Shaype

The biostimulator filler expands into Europe, signaling confidence in the PLLA-plus category.

By Evan at Inside MedSpa · Aug 15, 2026

Galderma has secured European Union approval for Restylane Shaype, its hybrid biostimulator filler combining PLLA with hyaluronic acid. The CE mark opens the EU market for a product positioned to compete with Radiesse (CaHA) and Sculptra (PLLA monotherapy) in the longevity and volumization segment.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/galderma-restylane-shaype-eu-approval/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Galderma Wins EU Nod for Restylane Shaype

Share

Discussion

Leave a comment

By the time it's news, it's too late.